Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Pfizer Inc.
Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.
Salon A-5 (Lower Level)
720 S Michigan Avenue
Chicago, IL 60605
Renal cell carcinoma (RCC) has been one of most difficult-to-treat of the solid tumors, and more recently, one of the most rapidly evolving fields in oncology. New data suggest impending changes to your practice in both early-stage and metastatic RCC, including novel indications, combination approaches, and optimized adjuvant strategies. The use of adjuvant therapy for RCC remains an area of controversy for which high-quality, well-coordinated, multidisciplinary care is of utmost importance to achieving optimal outcomes in the perioperative setting for your patients with RCC.
Please join us at Transforming Treatment Paradigms in Renal Cell Carcinoma: Understanding the Role of Risk Stratification and Emerging Data in the Adjuvant Setting, a satellite symposium that will be held in Chicago in June 2018. At this program, a multidisciplinary panel of renowned experts in RCC will guide you through an in-depth, up-to-date review of risk assessment in the early-stage RCC setting, patient selection for adjuvant systemic therapy, evidence from clinical studies of adjuvant therapy for RCC, and overall multidisciplinary care planning. To help you apply this information and to provide you with opportunities to interact with the faculty and each other, this activity includes case-based discussions and a Medical Crossfire® debate on key areas of controversy and clinical uncertainty around the use of adjuvant therapy for RCC.
By participating in this exciting program, you will learn:
This activity is supported by educational grants from Pfizer Inc.
This educational program is directed toward urologists, medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of renal cell carcinoma. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with renal cell carcinoma will be invited to participate.
Upon completion of this activity, participants will be able to:
Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology/Oncology
Deputy Director, Integrated Oncology Service Line
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018